Analysts Offer Predictions for Hims & Hers Health, Inc.’s Q2 2024 Earnings (NYSE:HIMS)

Hims & Hers Health, Inc. (NYSE:HIMS) – Seaport Res Ptn lifted their Q2 2024 earnings per share estimates for shares of Hims & Hers Health in a report issued on Monday, May 6th. Seaport Res Ptn analyst A. Kessler now anticipates that the company will post earnings per share of $0.05 for the quarter, up from their previous forecast of $0.02. Seaport Res Ptn has a “Buy” rating on the stock. The consensus estimate for Hims & Hers Health’s current full-year earnings is $0.11 per share. Seaport Res Ptn also issued estimates for Hims & Hers Health’s FY2024 earnings at $0.19 EPS and FY2025 earnings at $0.37 EPS.

Several other equities analysts have also issued reports on HIMS. Canaccord Genuity Group started coverage on shares of Hims & Hers Health in a report on Wednesday, April 10th. They set a “buy” rating and a $20.00 price objective on the stock. Imperial Capital raised Hims & Hers Health from an “in-line” rating to an “outperform” rating and set a $16.00 price target for the company in a research report on Wednesday, February 28th. SVB Leerink assumed coverage on Hims & Hers Health in a research report on Monday, February 26th. They set a “market perform” rating and a $10.00 price objective on the stock. Piper Sandler boosted their target price on shares of Hims & Hers Health from $11.00 to $13.00 and gave the stock a “neutral” rating in a report on Tuesday. Finally, Jefferies Financial Group restated a “hold” rating and issued a $15.00 price target (down from $17.00) on shares of Hims & Hers Health in a report on Tuesday, April 16th. Six investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, Hims & Hers Health presently has an average rating of “Moderate Buy” and an average target price of $15.07.

Hims & Hers Health Stock Performance

NYSE:HIMS opened at $12.36 on Wednesday. The firm has a 50-day simple moving average of $14.04 and a 200-day simple moving average of $10.35. Hims & Hers Health has a one year low of $5.65 and a one year high of $17.16. The firm has a market cap of $2.65 billion, a P/E ratio of -112.36 and a beta of 0.97.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, May 6th. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.03. Hims & Hers Health had a negative return on equity of 7.21% and a negative net margin of 2.70%. The firm had revenue of $278.20 million during the quarter, compared to the consensus estimate of $270.37 million. During the same period in the previous year, the company posted ($0.05) earnings per share. The firm’s quarterly revenue was up 45.8% on a year-over-year basis.

Insider Buying and Selling at Hims & Hers Health

In other news, insider Soleil Boughton sold 4,080 shares of the firm’s stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $10.03, for a total value of $40,922.40. Following the completion of the transaction, the insider now directly owns 154,345 shares in the company, valued at $1,548,080.35. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, CEO Andrew Dudum sold 97,208 shares of the business’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $9.58, for a total transaction of $931,252.64. Following the completion of the transaction, the chief executive officer now directly owns 51,653 shares in the company, valued at $494,835.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Soleil Boughton sold 4,080 shares of the stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $10.03, for a total value of $40,922.40. Following the sale, the insider now directly owns 154,345 shares in the company, valued at $1,548,080.35. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 736,191 shares of company stock worth $9,733,700. 31.63% of the stock is currently owned by insiders.

Institutional Trading of Hims & Hers Health

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. FNY Investment Advisers LLC acquired a new position in shares of Hims & Hers Health in the 4th quarter valued at $48,000. Cornerstone Investment Partners LLC purchased a new stake in shares of Hims & Hers Health during the 1st quarter worth about $161,000. EMC Capital Management grew its position in shares of Hims & Hers Health by 80.0% during the 3rd quarter. EMC Capital Management now owns 12,000 shares of the company’s stock valued at $79,000 after acquiring an additional 5,332 shares during the period. Belpointe Asset Management LLC purchased a new position in shares of Hims & Hers Health in the 3rd quarter valued at about $76,000. Finally, Certuity LLC acquired a new position in Hims & Hers Health in the 4th quarter worth about $109,000. 63.52% of the stock is owned by institutional investors and hedge funds.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.